Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations
Sponsor: 307 Hospital of PLA
A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by 307 Hospital of PLA and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 307 Hospital of PLA
- Beijing Clinical Service Center
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Fudan University
- Peking University Cancer Hospital & Institute
- Renmin Hospital of Wuhan University
- Zhejiang Cancer Hospital
- ZhuGuangYing
For direct contact, visit the study record on ClinicalTrials.gov .